Physician profile
Kleanthis Theodoropoulos
NPI 1710394325
$6,787.47
in general payments reported to CMS, 2019-2025
27 companies · $661 in 2025
The $661 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $559 · 2020: $293 · 2021: $2,596 · 2022: $880 · 2023: $1,383 · 2024: $416 · 2025: $661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,459.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,444.11 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Medtronic, INC. | $2,191.63 | 2021 | |
| Abiomed | $677.95 | 2020-2023 | Impella |
| Janssen Pharmaceuticals, INC | $221.33 | 2019-2024 | Xarelto |
| Boston Scientific Corporation | $173.69 | 2025 | Rotapro, Avvigo Guidance System |
| Nuwellis, INC. | $141.35 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $128.05 | 2019-2023 | Lifevest |
| Cardiovascular Systems INC. | $107.52 | 2020 | |
| Pfizer INC. | $90.77 | 2025 | |
| Merck Sharp & Dohme LLC | $79.92 | 2023-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.46 | 2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $66.97 | 2020-2024 | Wainua, Lokelma |
| Daiichi Sankyo INC. | $64.00 | 2023-2024 | Injectafer |
| Kiniksa Pharmaceuticals International, Plc | $45.04 | 2024 | Arcalyst |
| Scpharmaceuticals INC. | $36.43 | 2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| One Lambda, INC. | $33.63 | 2024 | |
| Janssen Scientific Affairs, LLC | $28.12 | 2019 | |
| Edwards Lifesciences Corporation | $27.27 | 2021 | |
| Bridgebio Pharma, INC. | $26.48 | 2025 | Attruby |
| Alnylam Pharmaceuticals INC. | $23.56 | 2020 | |
| Kiniksa Pharmaceuticals, LTD. | $21.15 | 2023 | Arcalyst |
| Chiesi USA, INC. | $20.00 | 2019 | |
| Shockwave Medical, INC | $19.17 | 2022 | |
| Davol INC. | $18.26 | 2020 | |
| Novartis Pharmaceuticals Corporation | $14.01 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $13.59 | 2023 | Inpefa |
| Z-Medica, LLC | $6.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kleanthis Theodoropoulos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.